Compare TR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | IMNM |
|---|---|---|
| Founded | 1896 | 2006 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Specialty Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | N/A | 2020 |
| Metric | TR | IMNM |
|---|---|---|
| Price | $38.39 | $18.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 143.2K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.70 | $7.96 |
| 52 Week High | $45.06 | $27.65 |
| Indicator | TR | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 34.55 |
| Support Level | $36.86 | $16.81 |
| Resistance Level | $43.20 | $19.16 |
| Average True Range (ATR) | 1.16 | 1.23 |
| MACD | -0.05 | -0.30 |
| Stochastic Oscillator | 37.85 | 0.43 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.